MWMark Weiss

Mark Weiss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Weiss has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COVID Border Accountability Project, a hand-coded global database of border closures introduced during 2020

    by Mary A. Shiraef, Cora Hirst, Mark A. Weiss, Sarah Naseer, Nikolas Lazar, Elizabeth Beling, Erin Straight, Lukas Feddern, Noah Rusk Taylor, Cayleigh Jackson, et al.

    Quantifying the timing and content of policy changes affecting international travel and immigration is key to ongoing research on the spread of SARS-CoV-2 and the socioeconomic impacts of border closures. The COVID Border Accountability Project (COBAP) provides a hand-coded dataset of >1000 policies systematized to reflect a complete timeline of country-level restrictions on movement across international borders during 2020. Trained research assistants used pre-set definitions to source, categorize and verify for each new border policy: start and end dates, whether the closure is “complete” or “partial”, which exceptions are made, which countries are banned, and which air/land/sea borders were closed. COBAP verified the database through internal and external audits from public health experts. For purposes of further verification and future data mining efforts of pandemic research, the full text of each policy was archived. The structure of the COBAP dataset is designed for use by social and biomedical scientists. For broad accessibility to policymakers and the public, our website depicts the data in an interactive, user-friendly, time-based map.


  • Open Access

    Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation

    by Lekha Mikkilineni, Kinjal Parikh, Fern Martin, Dolores Grosso, Benjamin Leiby, Onder Alpdogan, Matthew Carabasi, Margaret Kasner, Thomas R. Klumpp, Ubaldo Martinez-Outschoorn, et al.

    Background: Transplant related mortality(TRM) associated with allogeneic stem cell transplantation (HSCT) has necessitated risk-stratification that allows practitioners to make informed choices regarding patient selection for HSCT. Although pulmonary function testing (PFT) is obtained prior to HSCT at most institutions, and incorporated into common comorbidity indices (e.g. HCT-CI) there is no standard protocol to determine suitability for HSCT specific to lung disease. Also, there is a lack of data regarding the impact of tobacco use prior to HSCT. Recently, the association between smoking and kidney disease has gained attention. Tobacco-mediated kidney disease may be prognostic for renal failure post-HSCT. We studied the impact of tobacco use and lung function prior to HSCT on 30- and 100-day mortality as well as the frequency of post-HSCT respiratory and renal failure. Methods: We reviewed consecutive patients undergoing allogeneic HSCT at our institution from 2004 -2014 for acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and myelodysplastic syndrome (MDS). Smoking was categorized as never (0 pack years), low dose (Results: Of 373 subjects who underwent allogeneic HSCT, 315 (84%) had complete smoking histories (42% female, 58% male). AML (44.1%) accounted for the most frequent diagnosis followed by NHL (22.2%), ALL (14.3%), MDS (12.1%) and MM (7.3%). The 30 day mortality was 6.4%, 100 day mortality was 16.5%. 23.5% of patients required mechanical ventilation while 12.4% required dialysis. 46.7% of patients were smokers; 31.8% high dose smokers, 14.9% low dose smokers. There was an 11% increase in ventilator-dependency among high-dose smokers compared to none or low-dose (p=0.032), with a trend toward higher incidence of 100-day mortality with high dose smokers (31%) compared with low dose smokers (23.4%) and never-smokers (19.1%), (p=0.083). High dose smokers were more likely to have reduced pulmonary function with FEV/FVC < 70% (p=0.0004). Patients with FEV/FVC < 70% had a 14% increase in 100-day mortality with an almost 20% increased chance of ventilator dependency (p=0.022) and 17.6% increased incidence of dialysis dependency (p=0.032). DLCO did not correlate to any endpoint with statistical significance. Patients with MDS had the highest proportion of high dose smokers (47.4%; p=0.0023) and highest percentage of patients with FEV/FVC < 70% (18.4%, p=0.0037). Patients with MDS also had the highest 30-day mortality (18.4%, p=0.023), 100-day mortality (31.6%, p=0.0012), ventilator dependency (47.4%, p=0.0014) and dialysis dependency (31.6%, p=0.0036). Discussion: Our results differ from prior studies looking at the utility of FEV1 and DLCO in pre-HSCT PFTs as predictive markers; neither had prognostic value. We found that high dose smoking history and reduced FEV1/FVC were significantly associated with post-HSCT ventilator dependence, dialysis dependence and mortality. These results underscore the need for future studies that examine the relationship between smoking, lung function and renal failure post-HSCT. Our study did not demonstrate that low dose smoking predicts worse outcomes post-HSCT, but future studies may help provide patients with more accurate pre-HSCT counseling. Patients with MDS were the largest population of high dose-smokers and had the highest proportion of 100-day mortality, ventilator and dialysis dependency.


  • Open Access

    CD3/8 T-Cell Responses to CMV Reactivation in Patients Undergoing Haploidentical Transplants: A Retrospective Analysis

    by Mahasweta Gooptu, Benjamin Leiby, Onder Alpdogan, Matthew Carabasi, Joanne Filicko-O'Hara, Margaret Kasner, Thomas R. Klumpp, Ubaldo Martinez, Barbara Pro, Manish Sharma, et al.

    Introduction: Cytomegalovirus (CMV) reactivation post allogeneic hematopoietic stem-cell transplant (HSCT) has been associated with reduced early relapse, particularly in acute myeloid leukemia (AML) patients treated with myeloablative (MA) conditioning. The underlying biologic mechanisms are unclear, but upregulation of cytotoxic lymphocytes in response to CMV reactivation has been suggested. However, overall survival (OS) in these patients does not improve, and non-relapse mortality (NRM) appears worse in some studies. Separately, inadequate lymphocyte recovery at day 100 has been associated with poorer OS and relapse incidence. The possible association between lymphocyte responses to CMV reactivation and outcomes has not been extensively studied in patients undergoing haploidentical (HI) HSCT. We examined the association between CMV reactivation and OS, NRM, relapse incidence and day+90 CD3/8 T-cell counts in this patient population. Methods: Retrospective data analysis was performed on 134 evaluable patients undergoing haploidentical transplants (all patients who were alive and had not relapsed at day 90 post-HSCT). The patients primarily underwent a T-replete, 2-Step HI MA or reduced intensity (RIC) HSCT at Thomas Jefferson University between 2006 and 2014. In the 2-Step approach, a large fixed dose of T cells (2 x 108) is administered after conditioning (HSCT step 1), followed 2 days later by cyclophosphamide (CY) for T cell tolerization. Step 2 of the HSCT occurs with the infusion of a CD34 selected stem cell product, 1 day after the completion of CY. OS, NRM, and relapse incidence were compared between patients who were without versus with evidence of post HSCT CMV reactivation at day 90, which was defined by > 100 copies/ml by quantitative DNA PCR. Subgroup analysis to assess the relationship between CD 3/8 T-cell counts and CMV reactivation and their effect on OS using product limit survival estimates was performed on 118 patients with available CD3/8 T-cell counts at day +90. The median CD3/8 count for this group was 125 cells/μl; this level was used as the differentiator between high versus low CD 3/8 responses. Statistical analysis was performed with SAS. Results: CMV reactivation was detected in 62 of 134 (46.3%) patients. OS in CMV DNAemia+ vs. DNAemia- patients was 48% vs. 67% (Log Rank test, p=0.046). There were no significant differences in relapse and a non-significant increase in NRM based on CMV reactivation (Grays test, p=NS). CMV reactivation was strongly associated with increased CD 3/8 T-cell counts at day 90 post-HSCT (Wilcoxon test, p=0.0001). Using product limit survival estimates, we found that patients with no CMV reactivation and CD3/8 counts > 125 cells/μl at day 90 fared the best in terms of probability of OS at 2 years (84%), whereas those with CMV reactivation and CD3/8 counts < 125 cells/μl at day 90 fared the worst (50%). Patients with CD3/8 counts > 125 cells/μl reactivating CMV had OS rates of 59%. The difference in OS between these groups did not reach statistical significance, however. CD 3/8 T-cell counts greater than 125 cells/μl at day 90 were not associated with improved OS but were associated with a non-significant decrease in relapse incidence. These findings did not change after adjusting for acute graft-versus host disease, conditioning regimen (MA vs RIC) or disease subtype (AML versus non-AML). Conclusion: There was a significant association between CMV reactivation and quantitative CD3/8 T-cell responses in this population of patients primarily undergoing T-cell replete HI HSCT using the Jefferson 2-step approach. Despite this, CMV reactivation was associated with decreased OS in this population, perhaps related to the observed increase in NRM, although that did not reach statistical significance. There were no differences in relapse rates in patients with or without CMV reactivation. While not reaching statistical significance, there was a suggestion that higher CD3/8 T-cell counts at day +90 were partially protective against mortality in patients who developed a CMV DNAemia. Therefore, while T-cell responses to CMV may be helpful, other confounding factors such as coexisting GVHD, GVHD treatment with steroids, length of routine GVHD prophylaxis, and NK cell responses need to be studied in a multivariate setting to further explain the impact of CMV on OS.


  • Open Access

    Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

    by Neil E. Kay, Christopher R. Flowers, Mark Weiss, Nicole Lamanna, Ian W. Flinn, David Grinblatt, Thomas J. Kipps, Mark Kozloff, Susan Lerner, Jeff Sharman, et al.

    Abstract 3926